Company Profile


Hubei Guangchen Pharmaceutical Co., Ltd., established in 2014 with a registered capital of 40 million yuan, is a high-tech enterprise that integrates research, development, production, and sales of raw materials, pharmaceutical intermediates, formulations, and food additives. The company has developed a comprehensive development strategy that combines "pharmaceutical intermediates+raw materials+preparations". By establishing long-term and stable cooperative relationships with various domestic research institutes (such as Three Gorges University, Wuhan Engineering University, and Yantai Branch of Shanghai Institute of Pharmacy), the company strives to create a diversified growth strategy and improve its core competitiveness.

At present, the company mainly operates calcium hydroxybenzenesulfonate, allopurinol, tiopronin, ergosterol, and 3-amino-4-formamidopyrazole disulfate. The main product, calcium hydroxybenzenesulfonate raw material, has been associated with multiple pharmaceutical companies for consistency evaluation and passed on-site verification by the South Korean Food Safety Department (MFDS) in 2018; The product of its allopurinol raw material was publicly announced and transferred to A by the National Drug Administration in 2023. The research and development of the company's formulation products, allopurinol sustained-release capsules and linagliptin hydrochloride metformin sustained-release tablets, have entered the clinical trial stage and are expected to apply for listing with the National Drug Administration by the end of 2023.

The company established a research and development center in 2018, equipped with advanced research and development equipment and testing instruments. It has nearly 100 sets of research and development equipment, obtained 1 new technology/process, and formed 1 enterprise standard. The company has a sound research and development and technological innovation organizational management system, clear development plans and goals, standardized operation and management, high research and development efficiency, and has established a good industry university research cooperation relationship with Three Gorges University, providing competitive technical support for the company's sustainable development. As of now, the company has a workforce of 107, including 22 research and development personnel, 20 personnel with bachelor's degrees, and 12 personnel with intermediate professional titles.

In 2021, the company also invested in establishing Hubei Guangchen Biotechnology Co., Ltd., successfully developing international advanced anti-aging products—— β- Nicotinamide mononucleotide (NMN) is planned to be produced and sold next year.

In the future, the company will continue to increase research and development investment, target market demand, regularly introduce and absorb advanced projects in the industry, and strive to continuously form new growth points in the fields of raw materials, intermediates, and pharmaceutical products, striving to become an excellent pharmaceutical production enterprise in China.